Initiation: A novel immunotherapy approach targeting CD47
Trillium’s lead candidate, SIRPaFc, is an antibody-like fusion protein that blocks the activity of CD47, and thereby impedes a ‘do not eat signal’ expressed on several cancers including acute myeloid leukaemia (AML), which otherwise spares them from phagocytosis by the immune system. A Phase I AML study is planned to start in H215 and, with C$27.9m net cash as of 30 September 2014, Trillium is funded through this study’s completion. While still several years away from possible commercialisation, SIRPaFc’s immunotherapy mode of action could be applicable to multiple haematological and solid tumour types, potentially leading to well over $1bn in peak sales.Trillium Therapeutics is a Canadian public company developing stem cell-based therapies for cell therapy and regenerative medicine from academic sources for the purpose of commercialization.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.